

Haematologica
HAEMATOL/2018/191361
Version 2

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥ 60 years old with refractory/early relapsed acute myeloid leukemia

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Jeffrey E. Lancet, Michael D. Craig, Norbert Vey, Stephen A. Strickland, Gary J. Schiller, Elias Jabbour, Arnaud Pigneux, Heinz-August Horst, Christian Récher, Virginia M. Klimek, Jorge E. Cortes, Angelo-Michele Carella, Miklos Egyed, Utz Krug, Judith A. Fox, Adam R. Craig, Renee Ward, Jennifer A. Smith, Gary Acton, Hagop M. Kantarjian, and Robert K. Stuart

Disclosures: FR has received research funding from Sunesis, Amgen, Seattle Genetics, MacroGenix, Xencor, Bristol-Myers Squibb, and Abbvie; is an advisor/consultant for Jazz, Amgen, Seattle Genetics, Orsenix, and Sunesis; and has received honoraria from Jazz, Amgen, Orsenix, and Sunesis. ER has received research funding from Jazz and Novartis; is an advisor/consultant for Novartis; and a member of a speakers bureau for Incyte and Celgene. HS has nothing to disclose. JEL is an advisor/consultant for Biosight, Janssen, Astellas, Celgene, and Jazz. MDC has nothing to disclose. NV is an advisor/consultant for Sunesis. SAS has received research funding from Sunesis; is an advisor/consultant for Astellas, Boehringer-Ingelheim, Novartis, Pfizer, Sunesis, and Tolero. GJS has received research funding from, is an advisor/consultant for, and has received honoraria from Sunesis. EJ has nothing to disclose. AP has received research funding from Amgen, Novartis, Celgene, Gilead, Janssen, and Incyte and is an advisor/consultant for Jazz Pharmaceuticals, Amgen, Novartis, Sanofi, MSD, Celgene, Pfizer, Gilead, Janssen, Abbvie, Incyte, and Bristol-Myers Squibb. HA-H has received research funding from Amgen GmbH, and Regeneron Pharmaceuticals; is an advisor/consultant for Amgen GmbH, and Novartis AG; and a member of a speakers bureau for Celgene GmbH. CR has received research grants from Amgen, Novartis, Celgene, and Sunesis and is an advisor for Janssen, Sunesis, Jazz, Abbvie, Novartis, Celgene, and Pfizer. VMK has received institutional and salary support to conduct VALOR study from Sunesis and has also attended an advisory board for Sunesis. JEC has received research funding from Novartis, Pfizer, Jazz/Celator, Astellas, Daiichi, Immunogen, and Janssen and is an advisor/consultant for Novartis, Pfizer, Jazz/Celator, Astellas, Daiichi, Immunogen, and Janssen. A-MC has nothing to disclose. ME is an advisor/consultant for Novartis Hungary and Celgene Hungary. UK is an advisor/consultant for Sunesis, Jazz Pharma, Janssen, and Roche and has received honoraria from Sunesis and Jazz Pharma. JAF is a consultant for and employee of Sunesis. ARC has stock ownership in Sunesis. RW is an advisor/consultant for, a prior employee of, and owns stock in Sunesis. JAS is an employee of and owns stock in Sunesis. GA is a consultant for Sunesis. HMK has received research funding from Amgen, Ariad, Astex, BMS, Novartis, and Pfizer and has received honoraria from AbbVie, Actinium, Amgen, ARIAD, BMS, Immunogen, Orsinex, and Pfizer. RKS has received research funding from Sunesis, Ono Pharmaceuticals, Astellas, Agios, and Amgen; is an advisor/consultant for Ono Pharmaceuticals and Sunesis; and has received honoraria from Ono Pharmaceuticals and Sunesis.

Contributions: All authors made substantial contribution to analysis and interpretation of data; were involved in drafting the letter or revising it critically for important intellectual content; and read and approved the final letter for submission.